BTIG Research boosted their target price on Axsome Therapeutics from $62.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, December 23rd.

Source: https://www.americanbankingnews.com/2023/02/22/axsome-therapeutics-inc-nasdaqaxsm-stake-decreased-by-fora-capital-llc.html

Creative Planning’s holdings in Axsome Therapeutics were worth $458,000 as of its most recent filing with the Securities & Exchange Commission.

Source: https://www.americanbankingnews.com/2023/10/20/creative-planning-sells-371-shares-of-axsome-therapeutics-inc-nasdaqaxsm.html

ExodusPoint Capital Management LP purchased a new stake in Axsome Therapeutics in the first quarter valued at $5,963,000.

Source: https://www.etfdailynews.com/2023/12/16/axsome-therapeutics-axsm-buy-rating-reiterated-at-hc-wainwright/

Finally, Loop Capital initiated coverage on Axsome Therapeutics in a report on Tuesday, November 1st.

Source: https://www.americanbankingnews.com/2023/02/22/axsome-therapeutics-inc-nasdaqaxsm-stake-decreased-by-fora-capital-llc.html

Investors looking for exposure to the biotech industry and seeking a promising growth stock should consider Axsome Therapeutics.

Source: https://investorplace.com/2023/04/3-biotech-stocks-to-watch-after-johnson-johnsons-earnings-beat/

So far, in less than a year, Axsome has easily recouped its expenses (upfront payment) on Sunosi.

Source: https://seekingalpha.com/article/4598960-axsome-therapeutics-things-are-coming-together-nicely?source=feed_all_articles

Vanguard Group Inc. grew its position in shares of Axsome Therapeutics by 11.0% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/07/01/axsome-therapeutics-nasdaqaxsm-trading-down-4-4.html